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Clonidine inhibits fluid absorption in the rabbit proximal
convoluted renal tubule
DIANE ROUSE, SHIRLEY WILLIAMS, and WADI N. SUKI
Renal Section, Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
Clonidine inhibits fluid absorption in the rabbit proximal convoluted
renal tubule. Previous studies have shown that norepinephrine (NE)
and the beta-adrenoceptor agonist, isoproterenol (I). enhance fluid
absorption (Jv) in isolated, perfused proximal convoluted tubule seg-
ments (PCT). Pretreatment of PCT with the beta-adrenoceptor antago-
nist, propranolol, inhibited the action of NE and produced a significant
decline in Jv, suggesting modulation of Jv by both alpha- and beta-
adrenoceptors. The present studies further characterize the alpha-
adrenoceptor control of iv in isolated perfused PCT using specific
agonists and antagonists. Basal iv declined significantly with the
addition of the alpha2-adrenoceptor agonist, clonidine (l0 M), to the
bath; however, it was unchanged with the addition of the alpha1-
adrenoceptor agonist, methoxamine (1O_6 or iO M). Withthe addition
of 10—6 M isoproterenol iv increased significantly, and returned to
control values with the subsequent addition of clonidine (10-6 or IO
M). Pretreatment of PCT with the alpha2-adrenoceptor antagonist,
yohimbine (l0 M), or with pertussis toxin (100 nglml) did not interfere
with the stimulation of Jv by isoproterenol, but abolished the inhibition
of isoproterenol-stimulated Jv by clonidine. Thus, clonidine inhibits Jv
in PCT via an alpha2-adrenoceptor. This effect is mediated by a
pertussis toxin inhibitable GTP-binding protein, but not one that is
coupled to adenylyl cyclase.
Interest in the direct neural control of renal tubular function
has been rekindled by the morphological studies of Barajas and
colleagues [1, 2] which showed adrenergic nerve terminals in
direct contact with the basolateral membranes of certain tubular
epithelia. The neural control of salt and water handling has been
the subject of a number of important investigations. Two
reasons for the importance of these investigations to clinical
medicine are: 1) the putative role of renal nerves and circulating
catecholamines in the pathogenesis of disordered sodium me-
tabolism in certain disease states, such as salt-sensitive hyper-
tension [3, 4], cirrhosis [5, 61, and congestive heart failure [7, 8],
and 2) the renal tubular effects of "specific" adrenergic agonists
and antagonists used as antihypertensive agents.
Clearance and micropuncture studies have demonstrated that
sodium and fluid reabsorption in the proximal tubule decreases
with renal denervation [9, 10], and increases with renal nerve
stimulation [11] and catecholamine infusion [12], in the absence
of hemodynamic changes. Studies using the isolated perfused
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tubule have confirmed a direct effect of catecholamines on
proximal tubule reabsorption [13, 14]. Bello-Reuss [13] demon-
strated that fluid absorption increased with the addition of
norepinephrine to the medium bathing proximal convoluted
tubule segments microperfused in vitro. The effect was mim-
icked by isoproterenol and abolished by pretreatment with
propranolol, suggesting that beta-adrenoceptor stimulation en-
hances proximal tubule fluid absorption. Interestingly, propran-
olol not only abolished the stimulation of fluid absorption by
norepinephrine, but also unmasked a significant inhibition sug-
gesting an inhibitory aipha-adrenergic effect.
The present studies were designed to characterize the alpha-
adrenoceptor subtype responsible for the inhibition of fluid
absorption in the isolated, perfused proximal convoluted tu-
bule. The results show that the alpha2-adrenergic agonist,
clonidine, and not the alpha1-adrenergic agonist, methoxamine,
inhibits basal as well as beta-adrenergic-stimulated fluid absorp-
tion. The action of clonidine is inhibited by yohimbine and
pertussis toxin pretreatment.
Methods
General
Proximal convoluted tubule (PCT) segments were isolated
from the kidneys of 1.5 to 2.0 kg New Zealand white, female
rabbits, maintained on regular chow and tap water. A detailed
description of the method has been published previously [151
and is summarized as follows: Animals were killed by guillotine
or injection of T-61 Euthanasia Solution (Hoechst Roussel,
Somerville, New Jersey, USA). The left kidney was then
rapidly excised and decapsulated. A 1.0 mm transverse slice
was made, immersed in a chilled aliquot of the bath solution,
and 0.7 to 1.5 mm S2 segments of the superficial PCT dissected
free. Tubule segments were transferred to a perfusion chamber,
mounted on micropipettes and perfused as described by Burg
and colleagues [161. The artificial solution used to bathe the
segments consisted of the following (in mmol/liter): NaC1,
105.0; KC1, 5.0; NaHCO3, 25.0; Na acetate, 10.0; Mg SO4, 1.0;
glucose, 8.0; 1-alanine, 5.0; Na2HPO4, 2.3; CaCI2, 2.4; and 5.0
gIdl defatted bovine albumin (Sigma Chemical Co., St. Louis,
Missouri, USA). Osmolality was 300 mOsmlkg and pH and
PCO2 were maintained within normal limits by gassing with 5%
C02, 95% 02. Exhaustively dialyzed [3H-methoxy] inulin (ICN,
Irvine, California, USA), 30 pCi/mi, was added as a volume
marker to the perfusate, an ultrafiltrate of the bath. The
perfusate was driven by gravity at 15 to 19 ni/mm, and the bath
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exchanged continuously at 0.5mI/mm and maintained at 38°C.
Transepithelial potential difference was measured using agar-
ose-KC1 bridges and calomel electrodes,
Following the initiation of perfusion, a 30 to 45 minute
equilibration period was allowed, and then four control samples
of the fluid emanating from the tubule were collected using a
constant-volume constriction pipette. After the addition of
adrenergic agents to the bath, 30 minutes were allowed for
equilibration and four additional samples collected. The time
period for the collection of four samples was 20 to 30 minutes.
Previous time-control experiments have shown Jv to be stable
for 2.5 to 3.0 hours [17}. Viability is also assessed on each
tubule segment by visual examination of cellular integrity and
the maintenence of a transepithelial PD. Samples were depos-
ited in counting vials with a stream of distilled H20; 10.0 ml of
Biofluor (New England Nuclear, Boston, Massachusetts, USA)
was added to each vial and radioactivity measured in a liquid
scintillation spectrometer (Packard, Downers Grove, Illinois,
USA).
Adrenergic agents were obtained from Sigma Chemical Co.
Stock solutions of these agents were made daily and added to
the bath, in their final concentration, just prior to use. Pertussis
toxin was obtained from List Biological Laboratories, Inc.
(Campbell, California, USA). Containers of bath were pro-
tected from light throughout their use.
Protocols
Group I. a.) In five S2 segments (mean length, 1.1 0.1 mm),
following control collections the alpha1 -adrenergic agonist,
methoxamine, was added to the bath to a concentration of 10—6
M and further collections made. b.) In four additional segments
(mean length, 0.8 0.1 mm), the concentration of methoxamine
added to the bath was increased to l0 M.
Group II. In six S2 segments (mean length, 0.9 0.1 mm) the
protocol was similar to Group I, except the alpha2-adrenergic
agonist, clonidine, was added to the bath to a concentration of
i0 M.
Group III. In six 2 segments (mean length, 0.8 0.1 mm),
following control collections the beta-adrenergic agonist, iso-
proterenol, was added to the bath to a concentration of 10-6 M
and further collections made. Clonidine (l0 M) was then
added to the bath containing isoproterenol and final collections
made.
Group IV. To test the effect of a lower concentration of
clonidine and the reversibility of its effect, five S2 segments
(mean length, 1.0 0.1 mm) were bathed with isoproterenol
lO_6 M in the bath, and with isoproterenol and clonidine l0_6 M
in the bath. The order in which the baths were used was
randomly assigned among the individual experiments. Collec-
tions were obtained after equilibration of the segments with
each bath.
Group V. In this group of five S2 segments (mean length, 0.9
0.7 mm), the protocol used in Group III was repeated except
that pertussis toxin was added to the bath and to the dissection
medium in a concentration of 100 nglml. The segments were
dissected at room temperature and equilibrated with the bath
containing pertussis toxin for 60 minutes at 37°C before control
collections were made. Following the collections with isopro-
terenol in the bath, clonidine 106 M was added to the bath and
further collections made.
Group VI. In this group of six S2 segments (mean length, 0.8
0.1 mm) yohimbine (l0— M) was added to the bath immedi-
ately after the tubule was mounted for perfusion. Four collec-
tions were made following the initial equilibration period of 45
minutes, and following each of two additional 30-minute equil-
ibration periods.
Group VII. In this group of six S2 segments (mean length, 0.9
0.1 mm), the protocol followed was similar to that for Group
VI. Following control collections, either isoproterenol (106 M)
or isoproterenol and clonidine (l06 M) were added to the bath
containing yohimbine. The order in which the segments were
exposed to the baths, containing isoproterenol or isoproterenol
and clonidine, was randomly assigned among the individual
experiments.
Calculations and statistics
Fluid absorption (Jv) in ni/mm mm was calculated as fol-
Vi - Vo
Jv =
L
lows:
where Vo (nI/mm) is the volume of the constant volume
constriction pipette divided by the time interval of the collec-
tion, t; Vi is the content of [3H] in the collected fluid divided by
[3H]/nl of the perfusate, divided by t; and L is the length of the
tubule segment in mm, measured by a micrometer in the
eyepiece of the perfusion microscope.
For each experiment, the mean value for three to four
collections in each period is determined. The mean values the
standard error of the mean for each group are presented in the
tables. Student's t-test for paired samples was used to compare
the difference between two means from the same tubules,
unpaired T-statistic to compare two means from different tu-
bules, and analysis of variance to compare three means.
Results
Group I
In Group Ia, during the control period perfusion rate, Vi,
averaged 17.8 0.4 nl/min, Jv averaged 0.77 0.07 nllmm
mm, and PD averaged —1.3 0.5 mY. Following the addition
of methoxamine, lO_6 M, to the bath, Vi was unchanged, 18.3
0.3 nI/mm, as was Jv, 0.75 0.07 nl/mm mm, and PD, —1.7
0.7 mV. In Group Ib, during the control period Vi averaged 16.3
0.3 nl/min, Jv was 0.87 0.34 nl/mm mm, and PD was —1.3
0.2 mY. Following the addition of methoxamine iO' M to the
bath, no significant changes were observed. Vi averaged 16.7
0.2, Jv was 0.81 0.33 and PD was —1.7 0.2.
Group II
The results of these experiments are shown in Table 1. In
these tubules, Jv declined significantly after the addition of
clonidine to the bath. iv fell by 0.12 nllmm mm, a decline of
15.8% from control values. There were no significant differ-
ences in Vi or PD between the two periods.
Group III
The results of these experiments are shown in Table 2. Jv
increased significantly with the addition of isoproterenol to the
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Table 1. Effect of 10 M clonidine on Jv in S2 segments
Vi
ni/mm
iv
ni/mm . mm
PD
mV
Control 19.3 0.5 0.76 0.04 —1.3 0.5
Clonidine 18.4 0.8 0.64 0.07a —1.7 0.7
Abbreviations are: Vi, perfusion rate; iv, fluid absorption; PD,
transepithelial potential difference.
a Significant difference vs. control
Table 2. Effect of 10—6 M isoproterenol (I) and I + clonidine (Cl)
iO M on Jv in S2 segments
Vi iv PD
nI/mm ni/mm mm mV
Control 15.6 0.9 0.72 0.05 —1.3 0.2
Isoproterenol (I) 17.7 1.1 0.88 Ø,Ø5 —1.3 0.3
I + Clonidine (10 M) 14.8 1,0 0.60 011b —1.8 0.5
Vi, iv, and PD are described in Table 1.
a Significant difference from control
b Significant difference from I
Table 3. Effect of isoproterenol (1) 10—6 M and clonidine (Cl) 10—6 M
on iv in S2 segments
Vi iv PD
Tubule ni/mm nl/1nfl mm mV
number I I + Cl I I + Cl I I + CI
13.9 12.6 1.38 0.68 —3.5 —3.5
2 13.1 11.9 0.78 0.56 —2.0 —2.0
3b 15.2 14.8 0.78 0.61 —4.0 —4.0
4 14.8 14.7 0.61 0.37 —2.5 —3.0
5 14.6 12.7 0.74 0.57 —2.8 —2.8
Mean 14.3 13.4a 0.86 0.56a 30 —3.1
SEM 0.4 0.6 0.13 0.05 0.4 0.3
Vi, Jv and PD are described in Table 1.
a Significant difference vs. I
b Experiments in which I + Cl was used in the first bath and I atone
in the second bath.
bath, increasing by 0.16 nllmm. mm or 25.1%. The subsequent
addition of i0 M clonidine to the bath caused Jv to return to
a value numerically lower but not significantly different from
control (a fall of 0.28 nllmm . mm or 37.5%). PD was unchanged
by the addition of isoproterenol alone or isoproterenol and
clonidine to the bath.
Group IV
In these experiments, using 10—6 M clonidine in the bath, the
results were similar to those for Group III. iv was 32.6% lower
in the presence of clonidine and isoproterenol in the bath than
in the presence of isoproterenol alone (Table 3). The inhibitory
effect of clonidine was unaffected by the order in which the two
agents were added, suggesting that the effect of clonidine is
both real and reversible. Vi was significantly lower in the
presence of both isoproterenol and clonidine than in the pres-
ence of isoproterenol alone. It is unlikely that the decline in Vi
was responsible for the decline in Jv, since above 11.2 nI/mm,
Jv is independent of Vi [18]. There was no significant difference
in PD between the two periods.
Table 4. Effect of o
Jv in 2 segments
6 M isoproterenol (I), and l0_6
, pretreated with pertussis toxin,
M clonidine on
100 ng/ml
Vi Jv
ni/mm ni/mm mm
PD
mV
Pertussis toxin (PT)
PT + isoproterenol
PT + I + clonidine
15.1 0.8 0.72 0.05
15.2 0.8 0.87 0.05a
15.7 0.9 0.87 0.04a
—1.9 0.6
—2.6 0.7
—2.2 0.7
Vi, iv and PD are described in Table 1.
a Significant difference vs. PT
Table 5. Effect of isoproterenol (l0
on iv in yohimbine (l0 M)
6 M) and clonidine (10—6 M) + I
pretreated S2 segments
Vi
nI/mm
Jv
ni/mm mm
PD
mV
Yohimbine (Y) 13.6 0.6
Y ÷ isoproterenol 13.6 0.7
Y + I + clonidine 12.8 0.9
0.81 0.09
1.04 0.08a
1.03 0.08a
—1.8 0.5
—2.3 0.7
—2.0 0.6
a Significant difference vs. Y
Group V
The results of these experiments are shown in Table 4. Vi and
PD were not statistically different among the three periods:
pertussis toxin (PT) in the bath, PT and isoproterenol in the
bath, and PT, isoproterenol and clonidine in the bath. As in
Group III, iv increased significantly with the addition of iso-
proterenol to the bath, showing that pertussis toxin does not
inhibit the beta-adrenoceptor mediated action. However, the
inhibitory effect of clonidine on Jv was abolished by pertussis
toxin pretreatment.
Group VI
This group of tubule segments was studied as a time control.
There were no significant changes in Vi, iv or PD among the
three periods of study, with yohimbine in the bath. Vi averaged
13.1 0.3, 13.4 0.3, and 13.5 0.4 nL/min in the three
collection periods. During the same consecutive periods, Jv
was 0.94 0.18, 0.95 0.16, and 1.06 0.18 nI/mm. mm, and
PD was —1.1 0.5, —1.3 0.1, and —1.3 0.4 mV.
Group VII
The results for these tubule segments are summarized in
Table 5. There were no significant changes in Vi or PD among
the periods in which yohimbine, yohimbine and isoproterenol,
or yohimbine, isoproterenol and clonidine were present in the
bath. The addition of isoproterenol to the bath, containing
yohimbine, resulted in a significant increase in iv, showing that
the alpha2-adrenoceptor antagonist does not inhibit the action
of isoproterenol. However, the action of clonidine in this group
was completely abolished by pretreatment with yohimbine.
Comparison of the mean iv measurements in the control
periods for Groups VI and VII versus Groups I through IV
shows that there was no statistical difference between these sets
of experiments (P = 0.42). This suggests that yohimbine alone
does not alter Jv.
Discussion
The present results confirm the previously observed stimula-
tion of fluid absorption by isoproterenol [13], and demonstrate
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further that the alpha2-adrenergic agonist, clonidine, inhibits
basal and isoproterenol-stimulated fluid reabsorption in the
proximal convoluted tubule. In high concentrations clonidine
also inhibits basal fluid absorption in these segments. Clonidine
appears to act through a pertussis toxin-sensitive GTP-binding
protein. Although, clonidine may have some alpha1 agonist
activity, the more specific alpha1-adrenergic agonist, methox-
amine, had no effect on basal fluid reabsorption. Additionally,
the inhibitory effect of clonidine is blocked by pretreatment of
the tubule segments with yohimbine. These results are consis-
tent with an alpha2-adrenoceptor mediated action.
It is generally accepted that alpha2-adrenoceptors are present
in the kidney. They have been identified in the renal cortex of
several animal species, although their density varies among
these species [19—23]. In the kidneys from several species,
radioligand binding studies have shown that the alpha2 subtype
outnumbers the alpha1 subtype 2 or 3 to 1 [19, 20, 241. While
alpha2-adrenoceptors are found on the vasculature, several
studies have also suggested an extrajunctional position directly
associated with the tubular basement membrane. For instance,
alpha2 mediated effects are not observed with renal nerve
stimulation, but are observed with epinephrine infusion on the
background of alpha1-adrenoceptor blockade [25—27]. Also,
radioligand binding assays, using basolateral membrane vesi-
des [28—30] and isolated proximal tubule cells [31], have shown
alpha2-adrenoceptors directly in association with tubular epi-
thelium. This anatomic position suggests that alpha2-adreno-
ceptors play some role in proximal tubular function. Recently,
several distinct clonidine-activated receptors have been identi-
fied. Two alpha2-adrenoceptors have been identified, a high-
and a low-affinity type, each with different sensitivities to
sodium concentration and guanyl nucleotides [32]. Also, an
imidazole receptor previously found in brain has been demon-
strated in kidney tissue [33]. This receptor is activated by
exogenous clonidine and an endogenous clonidine-displacing
substance.
The functional role of alpha2-adrenoceptors is controversial.
Some studies have suggested that renal alpha2-adrenoceptors
do not play a direct role in the renal handling of salt and water
[34—37], while others suggest that they mediate enhanced salt
and water reabsorption [38—42]. Alpha2-adrenoceptors are in-
creased in three strains of genetically hypertensive rats prone to
salt retention [38—41]. Salt feeding further increases the density
of alpha2-adrenoceptors in these hypertensive rats. In normal
Sprague-Dawley rats treated chronically with alpha1-adreno-
ceptor blockade, alpha2-adrenoceptor density also increases
[42]. In isolated perfused kidneys from these rats, the antina-
triuresis evoked by renal nerve stimulation is partially reversed
by yohimbine, whereas in the kidneys from untreated rats,
yohimbine has no effect. The usual response to yohimbine
administration is antinatriuresis and hypertension, which has
been attributed to blockade of the presynaptic alpha2-adreno-
ceptor and subsequent increase in norepinephrine release [43].
In the normal rats with alpha1 blockade, the additional alpha2
receptors were proposed to occupy the postjunctional domain
previously occupied by the alpha1 subtype; however, the loca-
tion, vascular versus tubular, was not determined and may
represent a prejunctional position. The explanation offered for
the increase in alpha2-adrenoceptors in the normal rats is that
the alpha1 subtype tonically down-regulates their density but
when allowed to proliferate are responsible for the resulting
antinatriuresis [42]. Extrapolating to the genetically hyperten-
sive rats, the abnormal proliferation of the alpha2-adrenocep-
tors is proposed to be responsible for the salt retention in these
animals. An alternate explanation in these animals is that the
alpha2 subtype proliferates in response to the need to dispose of
an increased load of salt and water.
The present results suggest that alpha2-adrenergic agonists
are natriuretic and are consistent with the effects of these
specific agonists in vivo. Acute administration of alpha2-adren-
ergic agonists produces a natriuresis and diuresis in experimen-
tal animals and human subjects in the absence of changes in
GFR [44—46]. This natriuretic-diuretic response is enhanced
with prior saline expansion [45, 46], a maneuver known to
suppress sympathetic neural discharge. These results suggest
that a direct renal tubular effect is involved in the resulting
diuresis. Chronic treatment of hypertensive patients with the
alpha2-agonists, guanabenz [47], guanfacine [48], or clonidine
[49, 50] is not associated with the increased salt and fluid
retention characteristic of other antihypertensive agents [51-.
53]. Although the concentrations of clonidine used in the
present experiments are higher than the blood levels measured
in patients receiving clonidine therapy, the concentration of this
agent in kidney tissue has not been examined. The effect of
these relatively large concentrations of clonidine could repre-
sent the partial alpha1 agonist effect of this agent. However, the
addition of the alpha,-adrenergic agonist, methoxamine, to the
bath in concentrations of l06 or l0— M, had no effect on fluid
absorption in the S2 proximal convoluted tubule segments.
Additionally, pretreatment of the tubule segments with yohim-
bine completely abolishes the action of clonidine. These results
suggest that the inhibition of fluid absorption by clonidine is
mediated by an alpha2-adrenoceptor. The receptor type that
proliferates in the hypertensive and salt sensitive rats and the
type involved in the action of clonidine on Jv remains to be
determined.
Nord and colleagues [54] have shown that clonidine, acting
through an alpha2-adrenoceptor, stimulates Na/H exchange
in isolated rabbit proximal tubular cells. This action of clonidine
was inhibited by yohimbine and ethylisopropyl amiloride. This
group has also shown that amiloride competes with [3H]rauwol-
scine binding to these isolated cells. Our results are not consis-
tent with stimulation of Na/H exchange. The reason for the
discrepancy between our results and those of Nord et al is not
readily apparent. However, clonidine may affect more than one
transport system in the proximal tubule. In the study of Nord et
al, the isolated cells were incubated in a medium devoid of
organic solutes which have been shown to affect net fluid
absorption. Perhaps clonidine also modulates the reabsorption
of these other solutes. However, if this were the explanation, a
change in PD should have been observed. Also in this study, the
cells were treated with ouabain to inhibit Na ,K-ATPase. It is
possible that, in our studies, clonidine may modify an effect of
isoproterenol on this enzyme.
Several studies have shown that the effects of alpha2-adreno-
ceptor activation occur only after hormone activation of ade-
nylyl cyclase [25, 55—58]. Our studies show a greater effect of
clonidine on isoproterenol-stimulated than on basal fluid reab-
sorption. However, it is unlikely that this observation repre-
sents inhibition of adenylyl cyclase activity since cyclic AMP is
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known to inhibit sodium and water reabsorption in this segment
[59]. Additionally, isoproterenol does not stimulate adenylyl
cyclase activity in this segment [60]. A recent study by Beach
and colleagues [14] shows that norepinephrine stimulates fluid
absorption and oxygen consumption in isolated tubules and
Na ,KtATPase activity in cortical basolateral membrane yes-
ides. These results may explain the action of isoproterenol,
although preliminary results from this group suggest that both
an alpha2 and a beta agonist are required for the effect on
Na ,K-ATPase [61]. These preliminary results also suggested
that these effects are mediated by the phosphotidylinositol
system rather than adenylyl cyclase. The results from group V
of the present study suggest that clonidine exerts its effects
through a pertussis toxin-sensitive GTP-binding protein, al-
though they are not consistent with an inhibition of cyclic AMP
production. However, the GTP-binding proteins are now
known to be associated with a variety of cell receptors and
effector systems other than adenylyl cyclase, such as the
phospholipase A2 and C, and calcium and potassium channels
[62]. The particular effector system involved in action of
clonidine and isoproterenol in the PCT cannot be determined
from the present studies. While the present results suggest that
clonidine may be inhibiting the mechanism activated by isopro-
terenol, it is possible that the effects of these agents are
mediated by different mechanisms.
In summary, the results of this study provide evidence for a
direct effect of alpha2-adrenergic agonists on proximal tubule
salt and fluid reabsorption. This observation may explain, in
part, the diuretic property of these agents upon acute adminis-
tration, and the absence of salt and water retention when these
agents are given chronically.
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